Age disparity between a cancer population and participants in clinical trials submitted as a New Drug Application of anticancer drugs in Japan

Cancer

Volumn 109, Issue 12, 2007, Pages 2541-2546

  Hori, Akiko ^a   Shibata, Taro ^b   Kami, Masahiro ^c   Kusumi, Eiji ^c   Narimatsu, Hiroto ^d   Kishi, Yukiko ^e   Murashige, Naoko ^f   Mori, Kazuhiko ^a  

^a PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Anticancer drug; Clinical trial; Elderly patients; New Drug Application

Indexed keywords

AMRUBICIN; ANASTROZOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CAPECITABINE; CISPLATIN; CLADRIBINE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GEFITINIB; GEMCITABINE; GIMERACIL; GOSERELIN; HORMONE; IMATINIB; LEUPRORELIN; OTERACIL; OXALIPLATIN; PACLITAXEL; RITUXIMAB; TAMIBAROTENE; TEGAFUR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINORELBINE DITARTRATE;

ACUTE LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; INTERNET; JAPAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PARTICIPATION; PATIENT SELECTION; POPULATION GROUPS; RESEARCH SUBJECTS; THERAPEUTIC HUMAN EXPERIMENTATION; UNITED STATES;

EID: 34250188475     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22721     Document Type: Article

References (25)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
2. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the U.S. Food and Drug Administration. J Clin Oncol. 2004;22:4626-4631.
3. Hutchins LF, Unger IM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341: 2061-2067.
4. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383-1389.
5. Yee KW, Pater JL, Pho L, Zee B, Shi LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21:1618-1623.
6. Health Policy Bureau. Studies in support of special populations: geriatrics, 1993. PAB dated Dec. 2 (ICH-E7 Guideline): Notification No. 104 of the New Drugs Division.
7. Vestal RE. Aging and pharmacology. Cancer. 1997;80:1302-1310.
8. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol. 2001;51:615-622.
9. Ar'Rajab A, Dawidson I, Fabia R. Reperfusion injury. New Horiz. 1996;4:224-234.
10. Arrese JE, Pierard-Franchimont C, Pierard GE. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol. 1996; 18:196-198.
11. Arrese Estrada J, Stynen D, Van Cutsem J, Pierard-Franchimont C, Pierard GE. Immunohistochemical identification of Penicillium marneffei by monoclonal antibody. Int J Dermatol. 1992;31:410-412.
12. Farrell AT, Papadouli I, Hori A, et al. The advisory process for anticancer drug regulation: a global perspective. Ann Oncol. 2006;17:889-896. Epub 2005 Dec 15.
13. Nomura K. Cancer Statistics in Japan-2003. Tokyo: Foundation for Promotion Cancer Research; 2003.
14. Ministry of Health Labor and Welfare. Annual Report on Health, Labour and Welfare 2003-2004. Tokyo: Gyosei; 2004.
15. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112-3124.
16. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46:220-226.
17. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748-3757.
18. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15: 3266-3274.
19. Maloney DG, Grillo-Lopez AJ, White CA, et al. 1DEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
20. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994; 84:2457-2466.
21. National Cancer Institute Surveillance Epidemiology and End Result. Available at: http://seer.cancer.gov/statfacts/html/nhl.html. Accessed December 25, 2006.
22. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
23. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-1221.
24. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137-139.
25. Wadman M. London's disastrous drug trial has serious side effects for research. Nature. 2006;440:388-389.